JUBLPHARMA NSE filing

Jubilant Pharmova Q2 FY27 Revenue Up 21% to ₹2,370 Cr, PAT Declines 74%

The RealCase readMedium impact Neutral

Jubilant Pharmova reported Q2 FY27 revenue of ₹2,370 Cr, up 21% YoY. EBITDA was ₹255 Cr, with margins impacted by product mix and higher costs. PAT declined 74% YoY to ₹31 Cr. The company raised ₹800 Cr via NCDs for debt refinancing and capex. All business segments showed revenue growth.

Why it matters

The revenue growth is positive, but the substantial drop in profitability metrics (PAT and EBITDA margins) may concern investors. The successful fundraising provides financial flexibility, but the underlying operational challenges impacting margins need to be monitored.

The market read

While revenue showed strong growth, the significant decline in PAT and EBITDA margins due to specific business challenges (product availability, remediation costs) tempers the positive outlook. The fundraising is a positive, but the core profitability metrics are concerning.

Jubilant Pharmova Limited announced its financial results for the quarter and half year ended September 30, 2026. The company reported a revenue of ₹2,370 crore for Q2 FY27, marking a 21% year-on-year growth, driven by strong performance across all business segments, particularly in CDMO Sterile Injectables and Radiopharmaceuticals.

The company's EBITDA stood at ₹255 crore for the quarter. However, EBITDA margins saw a year-on-year decline of 708 basis points, primarily attributed to the unavailability of high-margin SPECT radiopharmaceutical products and increased operating expenses, including remediation costs at the CMO Montreal facility. Reported Profit After Tax (PAT) for the quarter was ₹31 crore, a decrease of 74% compared to the previous year, impacted by lower operating profitability and increased depreciation.

For the half year ended September 30, 2027, revenue grew by 19% YoY to ₹4,599 crore, with EBITDA at ₹523 crore and reported PAT at ₹87 crore.

Key business highlights include continued growth in Ruby-Fill® installations, release of Commercial SPECT radiopharmaceutical product from CMO Montreal, and a distribution agreement for a leading PET diagnostic product. The CDMO Sterile Injectables business signed a master services agreement with a large innovator pharma company for an oncology product. The Generics business saw significant revenue growth due to new product launches. In the Proprietary Novel Drugs business, initial clinical data from the JBI-802 Phase 1/2 clinical trial was presented, showing positive results. The company also successfully raised ₹800 crore through Non-convertible debentures to be utilized for debt refinancing and capex.

The Radiopharmaceuticals segment revenue grew by 18% to ₹342 crore, with EBITDA at ₹110 crore. The Radiopharmacy segment's revenue increased by 10% to ₹667 crore. The Allergy Immunotherapy business saw an 18% revenue growth to ₹230 crore. CDMO Sterile Injectables revenue grew by 33% to ₹522 crore, driven by incremental revenues from Line 3. The CRDMO business's Drug Discovery segment grew by 11% to ₹180 crore, while the API business revenue grew marginally by 2% to ₹140 crore. The Generics business revenue surged by 64% to ₹274 crore.

Filing to action

What to do with a filing like this

Jubilant Pharmova Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.

That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.

See the model portfolios
Primary source

A plain-language summary of a public exchange filing by Jubilant Pharmova Limited. Read the original for the full detail.

View original filing